Eupraxia Pharmaceuticals EPRX Ratios (2022-2026)

NASDAQ EPRX
$7.66 +0.16 (+2.13%)
As of: Sep 4, 2026 · 12:47 PM EDT
Reported Financials

Eupraxia Pharmaceuticals Quarterly Ratios

Periods 14 quarters
Latest Jun 2026

Eupraxia Pharmaceuticals ratios data for the quarter ended Jun 2026. These financial ratios cover 14 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Dec2022 Mar2023 Jun2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Efficiency
Assets AverageAssets Avg. 28.45M30.81M17.67M22.65M32.09M26.41M57.97M89.25M115.75M142.63M
Invested CapitalInvested Cap. 7.35M0.96M18.15M13.36M31.84M
Leverage & Solvency
Interest Coverage RatioInterest Cover 14.5732.5020.1622.530.01M0.05M
Debt Ratio 0.010.000.000.00
Times Interest Earned 14.5732.5020.1622.530.01M0.05M
Valuation
Price to EarningsP/E -11.72-12.07-15.05-17.29-23.49-33.06-18.05-22.86-18.23
Price to BookP/B 5.288.993.554.329.792.383.752.122.04
Enterprise Value 45.58M61.55M78.32M87.88M183.95M119.74M219.51M148.81M128.85M
EV to EBIT -7.18-10.27-10.40-12.99-21.04-18.80-13.14-11.77-8.91
EV to EBITDA -7.18-10.27-10.40-12.99-21.04-18.80-13.14-11.77-8.91
Market Capitalization 70.39M71.75M112.98M116.90M205.30M210.29M301.67M289.28M264.11M
Price to FCFP/FCF -9.16-7.07-19.06-20.04-25.19-47.30-31.64-29.46-20.44
EV to FCF -5.93-6.07-13.21-15.06-22.57-26.93-23.02-15.15-9.97
EV to CFO -5.92-6.04-13.11-14.64-22.12-26.57-22.57-14.67-9.84
Return Ratios
Return on Capital Employed [ROCE]ROCE -139.98%-187.12%-134.76%-54.30%-46.14%-41.02%-37.43%
Return on Assets [ROA]ROA -83.37%-156.87%-113.64%-82.14%-109.86%-50.71%-43.23%-38.40%-35.15%